Abstract：
GSK2251052 is a boron-containing antimicrobial agent in clinical development for the treatment of serious Gram-negative bacterial infections. These GSK2251052 quality control (QC) studies were performed to establish ranges for control strains (broth microdilution [BMD] MIC and disk diffusion zones) as follows: Pseudomonas aeruginosa ATCC 27853 (2-8 μg/mL and 15-24 mm), Escherichia coli ATCC 25922 (0.5-2 μg/mL and 23-30 mm), Haemophilus influenzae ATCC 49247 (0.25-1 μg/mL and 22-31 mm), Streptococcus pneumoniae ATCC 49619 (0.25-1 μg/mL and 19-28 mm), Bacteroides fragilis ATCC 25285 (1-4 μg/mL [BMD] and 1-4 μg/mL [agar dilution]), and Bacteroides thetaiotaomicron ATCC 29741 (1-8 μg/mL [BMD] and 2-8 μg/mL [agar dilution]). These ranges, approved by Clinical and Laboratory Standards Institute, will be crucial in accurately evaluating GSK2251052 in vitro potency.
摘要：
暂无翻译
